Adjuvant Sorafenib for the Treatment of HCC (Phase III STORM Trial)

August 26, 2014
Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.

Clinical Pearls

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.

  • The phase III STORM trial was a randomized, double-blind, placebo-controlled study of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma.
  • Results showed no difference in recurrence-free survival (33.4 months with sorafenib vs 33.8 with placebo).
  • It remains to be seen if targeting cancer cells in the adjuvant setting with an anti-angiogenic drug is correct or if another concept might be more appropriate.